Samir Sejpal, MD


Clinical Investigator
Focuses on head and neck, lung, prostate, breast, urologic and CNS cancers
Samir Sejpal, MD

Samir Sejpal, MD, MPH, is an eminently qualified radiation oncologist with advanced fellowship training in proton therapy and integrative medicine and broad expertise in Gamma Knife radiosurgery, stereotactic body radiotherapy, intensity-modulated radiotherapy and more.

After earning his bachelor’s degree with distinction in chemistry and political science from the University of North Carolina at Chapel Hill, Dr. Sejpal earned his medical degree from the UNC School of Medicine while simultaneously earning a Master of Public Health from the UNC School of Public Health. He next undertook his residency in radiation oncology at Northwestern University, completing his tenure there as Chief Resident, and went on to complete a one-year fellowship in proton therapy at the University of Texas – MD Anderson Cancer Center. He later continued his training with a two-year fellowship in integrative medicine at the University of Arizona.

Dr. Sejpal has lectured extensively on the latest radiation therapies, both as an invited speaker at prestigious medical forums and as a member of the medical faculty at the University of Texas and Northwestern University’s Feinberg School of Medicine. He is also a noted researcher and clinical investigator who is continually seeking new and more effective radiation therapies and protocols for all types of cancer.



  • Brachytherapy
  • Breast Cancer
  • Gamma Knife Surgery
  • Gynecologic Cancers
  • Head and Neck Cancers
  • Intensity Modulated Radiotherapy
  • Lung Cancer
  • Proton Beam Therapy
  • Stereotactic Body Radiotherapy
  • Testicular Cancer
  • Urologic Cancers

Awards & Honors

  • ACRO Travel Award
  • Goldberg Family Charitable Trust Travel Award
  • Fellow, National Comprehensive Cancer Network Annual Meeting
  • 4th Symposium on Combined Modality Therapy Travel Award
  • Medical Resident Forum Co-President


  • Outcomes of stage I-II testicular seminoma patients treated with dog-leg field radiotherapy (DLRT)
  • A review of management strategies of malignant gliomas in the elderly population
  • Institutional Principal Investigator: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors


  • Effect of Recombinant Human Deoxyribonuclease on Oropharyngeal Secretions in Patients with Head-and-Neck Cancers treated with Radiochemotherapy
  • Using intensity-modulated radiotherapy to spare the kidney in a patient with seminoma and a solitary kidney: a case report
  • Adaptive radiotherapy for head and neck cancer – dosimetric results from prospective clinical trial
  • Early findings on toxicity of proton beam therapy with concurrent chemotherapy for non-small cell lung cancer

Points of Difference

  • Award-Winning Innovations
  • Care, Support and Spa Services
  • Clinical Trials
  • Nationally Ranked Cancer Programs

Results & Outcomes

  • Advanced Diagnostics and Surgical Innovations
  • Award-Wining Technology
  • High Patient Satisfaction
  • Ongoing Research
(386) 231-4000